Researchers of a recent single-arm prospective trial evaluated the safety and efficacy of the Omnipod 5 automated insulin delivery (AID) system in adults with type 2 diabetes using insulin. Conducted across 21 US clinical centers, the study included 305 participants aged 18 to 75, most of whom were using multiple daily injections or basal insulin. After 13 weeks of AID use, participants experienced a significant reduction in hemoglobin A1c levels—from an average of 8.2% to 7.4%—as well as a 20 percentage point increase in time spent within the target glucose range (70–180 mg/dL). These results were consistent across various demographics and medication backgrounds, including those not taking GLP-1 receptor agonists or SGLT-2 inhibitors.

The trial also demonstrated that AID use did not increase hypoglycemia risk, with time spent in low glucose ranges remaining noninferior to standard therapy. Only one case of severe hypoglycemia occurred, and no instances of diabetic ketoacidosis or hyperosmolar hyperglycemic syndrome were reported. These findings suggest that AID systems, like Omnipod 5, could offer a safe and effective insulin management option for adults with type 2 diabetes, even in a diverse and medically complex patient population.

Reference: Pasquel FJ, Davis GM, Huffman DM, et al. Automated Insulin Delivery in Adults With Type 2 Diabetes: A Nonrandomized Clinical Trial. JAMA Netw Open. 2025;8(2):e2459348. doi: 10.1001/jamanetworkopen.2024.59348.